Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.77 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | BRD4 | O60885 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | GRM5 | P41594 | 1/20 | 0.45 |
| ▸ | S100B | P04271 | 1/20 | 0.44 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.42 |
| ▸ | DRD2 | P14416 | 2/20 | 0.42 |
| ▸ | MAOA | P21397 | 2/20 | 0.41 |
| ▸ | MAOB | P27338 | 2/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.41 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30875685 | 1.00 | MEN1 (0.77) | MEN1KMT2AGAASMN1; SMN2BRD4 | |
| SCHEMBL20214033 | 0.91 | MEN1 (0.64) | MEN1KMT2AGAASMN1; SMN2BRD4 | |
| SCHEMBL30883376 | 0.87 | MEN1 (1.00) | MEN1KMT2AGAASMN1; SMN2BRD4 | |
| SCHEMBL11923834 | 0.87 | MEN1 (1.00) | MEN1KMT2AGAASMN1; SMN2BRD4 | |
| SCHEMBL2061017 | 0.85 | MEN1 (0.64) | MEN1KMT2AGAASMN1; SMN2BRD4 | |
| SCHEMBL14993330 | 0.84 | MEN1 (0.54) | MEN1KMT2AGAASMN1; SMN2BRD4 | |
| SCHEMBL29989787 | 0.84 | MEN1 (0.54) | MEN1KMT2AGAASMN1; SMN2BRD4 | |
| Thalifoline SCHEMBL29961712 | 0.82 | MEN1 (0.77) | MEN1KMT2AGAASMN1; SMN2BRD4 | |
| SCHEMBL25946921 | 0.81 | MEN1 (0.75) | MEN1KMT2AGAASMN1; SMN2BRD4 | |
| SCHEMBL16519579 | 0.80 | MEN1 (0.79) | MEN1KMT2AGAASMN1; SMN2BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12577267-B2 | Pyrimidine compounds for use as MAP4K1 inhibitors | GLENMARK SPECIALITY S.A. (CH) | 2026-03-17 | — | — | US | disclosed |
| CN-117730083-A | Pyrimidine compounds as MAP4K1 inhibitors | 格兰马克专业公司 | 2024-03-19 | — | — | CN | disclosed |
| US-20230227483-A1 | PYRIMIDINE COMPOUNDS FOR USE AS MAP4K1 INHIBITORS | GLENMARK SPECIALITY S.A. (CH) | 2023-07-20 | — | — | US | disclosed |
| US-20230227483-A1 | PYRIMIDINE COMPOUNDS FOR USE AS MAP4K1 INHIBITORS | GLENMARK SPECIALITY S.A. (CH) | 2023-07-20 | — | — | US | disclosed |
| WO-2023281417-A1 | PYRIMIDINE COMPOUNDS FOR USE AS MAP4K1 INHIBITORS | GLENMARK SPECIALTY S.A. (CH) | 2023-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12577267-B2 | Pyrimidine compounds for use as MAP4K1 inhibitors | PTK2B, MAP3K10, MAP3K20 | MEN1 3993/4885KMT2A 1429/4885GAA 4486/4885 |
| US-20230227483-A1 | PYRIMIDINE COMPOUNDS FOR USE AS MAP4K1 INHIBITORS | MAP4K1, MAP3K4, MAP4K2 | MEN1 2549/4885KMT2A 2987/4885GAA 1046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.